2 results
Approved WMOCompleted
The primary objective is:* To determine the overall response rate (ORR) of 4 weekly infusions of obinutuzumab monotherapy (Induction I) in patients with rituximab-refractory follicular lymphoma.The secondary objectives are:* To determine theā¦
Approved WMOPending
To establish the safety and tolerablity of multiple doses of hLF1-11 given once daily for 10 days.